Financial Daily from THE HINDU group of publications
Wednesday, May 12, 2004

Cross Currency

Group Sites

Markets - Mutual Funds

Reliance MF launches pharma sector fund

Our Bureau

Kolkata , May 11

RELIANCE MF, which has just concluded allotment of units to investors in its power sector fund, has simultaneously launched a scheme dedicated to the pharmaceutical sector.

Reliance Power Fund, which has opened for ongoing subscription, has started with an NAV of Rs 10.04 (as on May 10). While the scheme's initial holdings are yet to become public, investment circles say it has stuck to securities issued by companies in the chosen sector and their associates. The pharma fund, for which investors in the power fund have been approached as well, will close for subscription on May 26.

Index fund mooted: Reliance MF has sought SEBI's approval for an index fund, which will offer two plans - based on Nifty and Sensex — to unitholders. Each plan will provide separate growth and dividend options. Reliance Index Fund will be the MF's first passively-managed equity product. Its existing offerings - Reliance Vision, Reliance Growth, Reliance Banking and Reliance Diversified Power - are all actively managed.

More Stories on : Mutual Funds | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Sensex to senses

Benchmark launches first split capital fund
Reliance MF launches pharma sector fund
Bear onslaught
Sensex sinks 229 on political worries
FIIs net sellers at Rs 595 cr on Monday
Pantaloon Retail retains investor interest
A spell of uncertainty ahead?
Bharat Forge scrip falls 5.3 pc on `poor Q4 nos'
Market players unsure; await poll results
Quick exit for profit booking
ACC: Outlook negative, short June futures
Panic over actual results continues

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line